Loading...
OTCMATHXQ
Market cap0kUSD
Dec 20, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Athersys Inc

Chart & Performance

D1W1MN
OTCM:ATHXQ chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-36.09%
Rev. gr., 5y
13.37%
Revenues
5m
-3.43%
2,152,00003,596,00003,260,0003,105,0002,159,0008,939,00010,344,0007,380,000755,000286,00010,298,00016,238,0002,843,00023,737,0005,517,0001,432,0005,514,0005,325,000
Net income
-68m
L-21.73%
-33,161,0000-14,599,000-1,511-18,926,000-17,992,000-15,366,000-11,377,000-13,746,000-14,735,000-30,743,000-22,082,000-16,422,000-15,337,000-32,241,000-24,283,000-44,582,000-78,765,000-86,955,000-68,061,000
CFO
-59m
L-22.62%
1,000-12,118,000-1,511-12,066,000-15,711,000-4,619,000-10,591,000-14,489,000-17,665,000-22,784,000-25,791,000-13,764,000-10,931,000-24,018,000-13,350,000-35,326,000-61,810,000-76,185,000-58,950,000

Profile

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
URL
https://www.athersys.com/home/default.aspx
IPO date
Apr 23, 2007
Employees
24
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,325
-3.43%
5,514
285.06%
Cost of revenue
80,914
91,145
Unusual Expense (Income)
NOPBT
(75,589)
(85,631)
NOPBT Margin
Operating Taxes
(4,474)
Tax Rate
NOPAT
(71,115)
(85,631)
Net income
(68,061)
-21.73%
(86,955)
10.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
31,020
64,263
BB yield
-309.16%
-31.75%
Debt
Debt current
746
1,011
Long-term debt
17,370
19,532
Deferred revenue
5,199
5,199
Other long-term liabilities
(4,665)
(5,199)
Net debt
9,078
(16,864)
Cash flow
Cash from operating activities
(58,950)
(76,185)
CAPEX
(397)
(1,360)
Cash from investing activities
(262)
(1,360)
Cash from financing activities
30,843
63,406
FCF
(44,577)
(95,128)
Balance
Cash
9,038
37,407
Long term investments
Excess cash
8,772
37,131
Stockholders' equity
(655,860)
(583,101)
Invested Capital
641,974
610,247
ROIC
ROCE
544.35%
EV
Common stock shares outstanding
11,945
8,971
Price
0.84
-96.28%
22.57
-48.42%
Market cap
10,034
-95.04%
202,431
-38.30%
EV
19,112
185,567
EBITDA
(74,169)
(84,204)
EV/EBITDA
Interest
4,475
Interest/NOPBT